Eledon Pharmaceuticals, Inc. ELDN 深 滬
已收盤 05-08 16:00:00 美东时间
3.88
+0.020
+0.52%
華盛通- 最 高3.995
- 今 開3.87
- 成交量 111.21万股
- 最 低 3.84
- 昨 收 3.86
- 總市值 2.99亿
- 52周最高 4.60
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 1.35
- 委 比 88.31%
- 總股本 7718.78万
- 歷史最高 154.98
- 量 比 0.89
- 振 幅 4.02%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eledon Pharmaceuticals Files Prospectus For Offering $500M Securities
https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
05-02 04:14
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
04-30 20:01
NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that
04-20 19:39
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Issued on behalf of Avaí Bio, Inc. USANewsGroup.com News Commentary VANCOUVER, BC, April 6, 2026 /PRNewswire/ -- The global cell therapy manufacturing market is on track to nearly double, fr...
04-07 01:10
NewcelX prices $1.35M equity financing
NewcelX (NCEL) announced on Wednesday that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last clo...
04-01 20:10
NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes programZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical
04-01 19:32
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Zurich-based biopharmaceutical company NewcelX Ltd. announced a private placement of 490,907 common shares at $2.75 per share, a 30% premium over its March 31 closing price, raising funds to advance its lead Type 1 Diabetes program NCEL-101 in collaboration with Eledon Pharmaceuticals. The offering also includes warrants for 687,270 additional shares at $3.025 per share and is expected to close by April 15. Proceeds will support NCEL-101 developm...
04-01 11:21
Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the
03-20 05:13
美股夜盘 | Health In Tech, Inc. Class A涨52.94%，ZenaTech, Inc.涨18.42%
Health In Tech, Inc. Class A涨52.94%；ZenaTech, Inc.涨18.42%；万达生物制药涨10.81%
03-18 13:02
